warning

Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Title  
COG AALL0932 Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia
Brief Description  
AALL0932 will explore the delivery of Maintenance therapy for children with AR B-precursor ALL. This study will compare 2 different doses of methotrexate during Maintenance administered with and without a reduced frequency of vincristine/dexamethasone (VCR/DEX) pulses, every 12 weeks compared to every 4 weeks, respectively, in a 2 x 2 design.
Who may be Eligible  
Patients must have newly diagnosed NCI Standard Risk B-precursor ALL. Patients with Down syndrome are also eligible.
Patients must be > 365 days and < 10 years of age.
Patients must have an initial white blood cell count < 50 000/•L

 

Speciality/Disorder  
Leukemia
IRB Number  
10-10-08B
Principal Investigator  
Kaplan, Joel

For More Information, Contact  Wendy  C, Bissette
Phone:  (704) 355-9081  Fax:  (704) 355-1188  
Email:  Wendy.Bissette@carolinashealthcare.org
Address:1025 Morehead Medical Drive Charlotte, NC 28204
Close